Recently, Anqilai, an innovative drug for the treatment of Parkinson's disease, was jointly developed by the Danish company Lingbei and Teva. (Rasagiline Mesylate Tablet) officially announced its listing in China.
Anqilai is the latest generation of monoamine oxidase B inhibitors currently marketed in China. It can be used for monotherapy in patients with primary Parkinson's disease and combination therapy in patients with peripheral fluctuations. Research data at home and abroad confirmed that Anqi came? Monotherapy can significantly improve the patient's exercise and non-motor symptoms; in combination therapy, the levodopa treatment effect can be optimized to further effectively control symptoms and reduce exercise fluctuations.
Early diagnosis and treatment, improve the quality of life of patients
It is estimated that more than 2.5 million people in China suffer from Parkinson's disease. This is a neurological disease that is highly disabling and seriously affects the quality of life, which places a heavy burden on patients, their families and society. Health economics research shows that the average annual direct expenditure of each Parkinson's disease patient is 15,660 yuan, and the annual indirect expenditure is 4,500 yuan.
Medical Valley reporter interviewed members of the Education Committee of the Asia-Pacific Branch of the International Parkinson's Disease and Movement Disorders Association, member of the Standing Committee of the Chinese Medical Association Neurology Branch and member of the Parkinson's Disease and Movement Disorders Group, and deputy director of the Department of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Professor Qin learned that although there are diagnostic standards and treatment guidelines in China, the number of Parkinson's disease specialists is relatively small and the people's knowledge of the disease is insufficient. Therefore, there are problems in delay diagnosis, missed diagnosis and misdiagnosis.
Member of the Standing Committee of the International Parkinson's Disease and Movement Disorders Society, Vice President of the Neurological Physician Branch of the Chinese Medical Association and Chairman of the Parkinson's Disease and Movement Disorders Committee, and Professor Chen Shengdi, Director of the Department of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, said: More than half of the patients in China still cannot be identified and diagnosed. Almost half of the patients have not been effectively treated. We need to strengthen the science popularization of Parkinson's disease and need to further improve the diagnostic ability and treatment level of clinicians for Parkinson's disease. Allowing almost half of the patients who are currently untreated can receive effective treatment and benefit more patients."
Professor Chen Wei, director of the National Center for Geriatric Disease Clinical Research, director of the Parkinson's Disease Research Institute of the Beijing Institute of Brain Diseases, and director of the Department of Geriatrics of Xuanwu Hospital, reminded: "Parkinson's disease may have some signs and symptoms of the prodromal period, which is characterized by Specific non-motor symptoms such as insomnia, multiple dreams, depression, anxiety, etc. As the disease progresses, these symptoms become more common and apparent."
If Parkinson's disease is not treated in time, it can cause many complications. Common constipation, hypotension, and urinary tract infections are the most common comorbidities of Parkinson's disease, and less common such as depression, type 2 diabetes, back problems, arthritis, urinary incontinence, atrial fibrillation, and dementia The quality of life has a serious impact.
In fact, although Parkinson's disease itself is not fatal, comorbidities may reduce life expectancy and quality of life. To this end, in 2016, the Chinese version of the Parkinson's Disease and Movement Disorders Group of the Chinese Medical Association, the new version of the Chinese Parkinson's disease (PD) treatment recommendations pointed out: Parkinson's disease is a highly complex and unhealable disease, so the guide advocates " Once an early diagnosis is made, treatment should be started as soon as possible."
Regrettably, the current form of prevention and treatment of Parkinson's disease in China is severe. At present, the public's understanding of Parkinson's disease and its symptoms is still relatively limited. According to a survey of 6,000 public respondents in China, more than 80% of respondents in China do not understand Parkinson's disease.
However, recent research shows that many people experience gastrointestinal dysfunction in the first ten to twenty years after a patient is diagnosed with Parkinson's disease. The intestine may become a relevant peripheral biomarker method and eventually open up treatment for Parkinson's. New treatment for the disease.
In this regard, Professor Chen Haibo, member of the Standing Committee of the Chinese Medical Association Neurology Branch and head of the Parkinson's Disease and Movement Disorders Group, and director of the Department of Neurology, Beijing Hospital, pointed out: "With the emergence of new diagnostic tools such as biomarkers, early diagnosis and early treatment intervention May contribute to the treatment of Parkinson's disease and provide a better quality of life in the future."
Improve treatment accessibility and help prevent and control system construction
As the population ages, it is expected that by 2030, the number of patients with Parkinson's disease in China will surge to about 5 million, and the number of patients will account for more than half of the world. Parkinson's disease is becoming one of the major challenges facing China's road to promoting healthy aging. . According to a survey of 6,000 people, the rate of visits to Parkinson's disease is only about 40%, and <40% of patients with Parkinson's disease receive regular medical treatment.
Professor Chen Wei said: "Although there is no treatment available to alleviate or cure Parkinson's disease so far, effective treatments such as drugs can significantly improve the quality of life of patients. Therefore, improve the accessibility of drugs and Getting a diagnosis is key to improving patient outcomes and better coping with the increasing burden of Parkinson's disease."
In this regard, Professor Chen Haibo also said: "Patients can not wait until Parkinson's disease affects the quality of life before treatment. Once diagnosed, drug treatment should be carried out early, and drug treatment in the early stage of the disease will help delay the progression of Parkinson's disease symptoms. Give patients a better quality of life."
Currently, the principle of drug treatment for Parkinson's disease is to increase the level of dopamine in the brain, improve symptoms and reduce motor complications, and improve the quality of life of patients. It is understood that compared with developed countries, the types and quantities of Parkinson's disease treatment drugs in China are relatively small, and the listing of Anqilai is the gospel of patients with Parkinson's disease.
Anqilai is a new type of B-type monoamine oxidase (MAO-B) inhibitor that can effectively improve the main symptoms, reduce fluctuations, improve early morning closure, and improve quality of life. It can be used for early patients. It can also be used in patients with motor complications in the middle and late stages.
Professor Zhang Zhenxin, director of the National Neurological Disease Clinical Research Center and director of the Chinese Academy of Medical Sciences Peking Union Medical College Hospital, said that compared with other drugs, Anqi has fewer side effects, the drug itself does not cause turmoil, no addiction, daytime Side effects such as lethargy and hallucinations.
It is reported that Anqi has accumulated a large number of efficacy and safety data in the elderly population of listed countries. Regardless of whether it is a single drug or a combination therapy with levodopa, Anqi has been consistently recommended by the International Guidelines. In China, Anqilai has been recommended by the Chinese Medical Association Neurology Branch Parkinson's Disease and Movement Disorders Group's "Guidelines for the Treatment of Parkinson's Disease in China (Third Edition)" to improve the "end-of-agent deterioration, switching phenomenon" Preferred drug.
In this regard, Professor Chen Wei pointed out: "In recent years, China has accelerated the process of listing innovative drugs, which has greatly improved the accessibility of drugs. However, due to the lack of a medical team capable of managing Parkinson's disease, there are still many patients. To get treatment, we need to strengthen the construction of the talent team, and we need more trained and accurate diagnosis of the disease, Parkinson's disease and movement disorders experts, improve and standardize the accessibility of Parkinson's disease treatment, meet the patient's Medical needs."
At present, Anqilai has been listed in more than 50 countries and regions around the world. In many countries, An Qilai? It has become the newest prescription for the treatment of Parkinson's disease. At the same time, An Qilai? The Chinese market is being actively deployed and has entered the medical insurance catalogue of Guizhou Province. Ke Yihan, president and general manager of Lingbei China, said that he hopes that An Qi will come? It can cover China's vast market faster and bring better treatment and care to many patients with Parkinson's disease.
Biologics are drugs made from complex molecules manufactured using living microorganisms, plants, or animal cells.Anti-rabies Vacine for Human is a preparation of rabies fixed virus CTN-1V inoculated into Vero cell , which is used for the prevention of the rabies disease.
Biological Product,Rabies Symptoms Human,Human Rabies Symptoms,Human Rabies Signs
Changchun Zhuoyi Biological Co., Ltd , https://www.zhuoyibiological.com